Catalyst Pharmaceutical Partners, Inc. to Present at 15th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

CORAL GABLES, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that the company will present at the 15th Annual BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City, New York. Patrick J. McEnany, Catalyst's Chief Executive Officer and Steven Miller, PhD, Catalyst's Chief Scientific Officer/COO, will provide an overview of the company and its progress in key programs on Monday, February 11, 2013, at 4:00 p.m. Eastern Standard Time. The company's presentation materials will be posted at the company's website, http://www.catalystpharma.com http://www.globenewswire.com/newsroom/ctr?d=10020534&l=1&a=http%3A%2F%2Fwww.catalystpharma.com&u=http%3A%2F%2Fwww.catalystpharma.com%2F , in the Investors section, under "Events and Presentations".

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette Syndrome. Catalyst's lead candidate, Firdapse for the treatment of LEMS, is currently undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, like post-traumatic stress disorder, Tourette Syndrome, and movement disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including whether any of the Company's product candidates will ever be approved for commercialization and those factors described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany

Catalyst Pharmaceutical Partners

Chief Executive Officer

(305) 529-2522

pmcenany@catalystpharma.com

Melody Carey

Rx Communications Group

Co-President

(917) 322-2571

mcarey@rxir.com